Berotec

Berotec

fenoterol

Manufacturer:

Boehringer Ingelheim
Concise Prescribing Info
Contents
Fenoterol HBr
Indications/Uses
Symptomatic treatment of acute asthma attacks. Prophylaxis of exercise-induced asthma. Symptomatic treatment of bronchial asthma & other conditions w/ reversible airway narrowing eg, chronic obstructive bronchitis. Concomitant anti-inflammatory therapy should be considered for patients w/ bronchial asthma & steroid responsive COPD.
Dosage/Direction for Use
Acute asthma episodes 1 actuation. A 2nd actuation may be required if an attack has not been relieved after 5 min. Prophylaxis of exercise-induced asthma 1-2 actuation/administration up to max: 8 actuation daily. Bronchial asthma & other conditions w/ reversible airways narrowing 1-2 actuation/administration up to max: 8 actuation daily.
Contraindications
Hypersensitivity to fenoterol HBr or to any excipients of Berotec. Hypertrophic obstructive cardiomyopathy, tachyarrhythmia.
Special Precautions
Insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma. Discontinue immediately if paradoxical bronchospasm occurs. Underlying severe heart disease. Severe asthma. Acute rapidly worsening dyspnoea. Patients on prolonged regular use must be evaluated for additional or increase of anti-inflammatory therapy. 1st trimester of pregnancy & lactation.
Adverse Reactions
Hypersensitivity reactions; hypokalaemia; agitation, nervousness; tremor, headache, dizziness; myocardial ischaemia, arrhythmia, tachycardia, palpitations; paradoxical bronchospasm, cough, throat irritation; nausea, vomiting; hyperhidrosis, skin reactions eg, rash, pruritus, urticaria; muscle spasm, myalgia, muscular weakness; increased systolic BP, decreased diastolic BP.
Drug Interactions
β-adrenergics, anticholinergics & xanthine derivatives may enhance the effects of Berotec. Increased risk of hypokalemia w/ xanthine derivatives, corticosteroids & diuretics. Serious reduction in bronchodilatation w/ concurrent administration w/ β-blockers. Enhanced action of β-adrenergic agonists w/ MAOIs or TCAs. Inhalation of halogenated hydrocarbon anesth may increase susceptibility to CV effects of β-agonists.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AC04 - fenoterol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Berotec MDI 100 mcg/actuation
Packing/Price
(200 puffs) 10 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in